Stacie B Dusetzina

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1251-60. 2012
  2. ncbi Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
  3. ncbi Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacotherapy 32:1085-94. 2012
  4. ncbi Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 64:83-7. 2013
  5. ncbi Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Psychiatr Serv 62:1443-9. 2011
  6. ncbi Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012

Detail Information

Publications6

  1. ncbi Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1251-60. 2012
    ..We examine subsequent changes in incident and prevalent SGA use among individuals with severe mental illness...
  2. ncbi Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
    ..The objectives of the study were to identify one-year health services utilization and treatment costs among youths newly diagnosed as having bipolar disorder...
  3. ncbi Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacotherapy 32:1085-94. 2012
    ..To estimate the treated prevalence of bipolar disorder in a privately insured population, describe the characteristics of children and adolescents receiving these diagnoses, and describe patterns of their psychotropic drug therapy...
  4. ncbi Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 64:83-7. 2013
    ..S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown...
  5. ncbi Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Psychiatr Serv 62:1443-9. 2011
    ..This study examined the extent to which children with bipolar I disorder received recommended treatment of mood-stabilizer or second-generation antipsychotic monotherapy and factors associated with its receipt...
  6. ncbi Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012
    ..To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes...